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Abstract
Metal ions are believed to participate in many neurodegenerative conditions. In excitotoxic cell
death there is convincing evidence for the participation of Ca2+ and Zn2+ ions although the exact
molecular mechanisms by which these metals exert their effects are unclear. Only in one instance
has the metal binding site of metalloenzymes been exploited for therapeutic purposes and this is
the use of Li+ in the treatment of bipolar affective disorder. Again the exact molecular target is not
clear but is likely to involve a Mg2+-dependent enzyme of an intracellular signalling pathway. In
Parkinson’s disease, the selective loss of dopaminergic neurones in the substantia nigra ma/b.e
caused by radical-mediated damage and there is good evidence to suggest that Fe2+ or + =s
important in promoting formation of radical species. The evidence that free radicals are important in
mediating other neurodegenerative conditions is less strong but still substantial enough to suggest
that removal of reactive oxygen species or preventing their formation may be a valid approach to
therapy.
Introduction
In this article, rather than describe the role of metal ions in normal neuronal function, have focused
on abnormal neuronal conditions and the role of metal ions in causing or in preventing them i.e
neurotoxic metals and metal-based therapeutics. My reason was principally to reduce the scope of
the topic to manageable proportions, but metal ions seem to play an important part in neuronal cell
death and a better understanding of their properties could lead to improved therapeutics. Since so
many different metals ions are toxic have also chosen to concentrate on those which have a normal
physiological function and which become neurotoxic when this is disturbed.
Many divalent and trivalent metal ions are neurotoxic and there are a variety of mechanisms which
contribute or could contribute to cell damage. Probably of greatest importance are effects involving
ion channels. Calcium channels are prime targets for blockade by divalent cations1,2, but the same
channels may also transport toxic metals into the cell interior to act on intracellular targets3. Ligand-
gated ion channels, such as the NMDA receptor, can also act both as targets for metal ions and as
transporters4,5. There is good evidence that the toxicity of certain metals such as Zn2+ for example,
is absolutely dependent on transport6. The true targets therefore for these (and probably other
metals) are intracellular and could in principle involve enzyme inhibition or activation, promotion of
free radical formation leading to protein and membrane damage, protein modification and cross-
linking etc.
Knowledge of the mechanisms of metal-based toxicity should provide ideas about metal-based
therapeutics for CNS disorders. The use of lithium salts in the treatment and prophylaxis of bipolar
affective disorder (manic depression) remains, however, the sole example. While the detailed
mechanism is not clear at this stage, the idea that lithium ions interfere with intracellular signal
transduction pathways seems to have taken root7. In the same way that Zn2+ toxicity, for example,
could result from inhibition of divalent metal- dependent processes in the cell, it seems probable
that the therapeutic benefit of Li+ could also derive from an effect on a Mg2+-dependent enzyme7.
The lack of marked selectivity of enzymes for metal ions could explain the toxicity of Li+ at higher
concentrations.
An entirely different approach to metal-based drugs also emerges from an understanding of metal-
based toxicity. The growing interest in free radical-mediated cell death, in which metal-catalyzed
reactions play an important role, has spawned a number of approaches to neuroprotection in
response to acute injury or chronic disease. One such is the use of organomanganese complexes
which catalyze the dismutation of reactive oxygen species (O2.’, H202)8. These compounds may
turn out to have utility not only in neurological disorders such as stroke, but also in protecting other
tissues subject to ischaemia/reperfusion injury such as the heart.
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Exicitotoxicity, Ca2+ and Zn2+
The main excitatory neurotransmitter in the brain is glutamate. The target receptors for glutamate
released at glutamatergic synapses are a groupof ligand-gated ion channels which permit entry of
Na+ ions to produce a depolarization of the cell9. The family of receptors most involved in normal
synaptic transmission are the AMPA/KA group, named after selective agonists for these classes.
The NMDA class of glutamate-gated ion channels is blocked by Mg2+ in a voltage-dependent
manner, i.e. the channels do not function when the cell is polarizedO. Following interruption to the
blood supply to the brain, as in stroke, normal mechanisms regulating the synaptic concentration of
glutamate fail11 (Fig. ).
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Fig.1. Normal and ischaemic glutamatergic synapses
Energy-dependent processes such as the re-uptake of glutamate into pre-synaptic terminals or
neighbouring glial cells cease and the terminal transporter reverses leading to a huge increase in
glutamate release. Excessive stimulation of post-synaptic glutamate receptors leads to marked
depolarization, and relief of the voltage-dependent block of NMDA receptors. This class, unlike the
majority of AMPA/KA receptors, also allows Ca2+ entry12, and under these conditions the excess of
intracellular Ca2+ overwhelms the buffering capacity of mitochondrial storage and sets in motion a
train of events which leads, eventually, to cell death. While Ca2+ has been identified as one of the
villains for some time, the exact sequence of events is still undefined in detail. Ca2+ overload can
lead to mitochondrial damage13 and metabolic failure of the cell even if blood supply is restored.
Ca2+ also activates proteases such as calpain which may lead to conversion of xanthine
dehydrogenase to xanthine oxidase producing potentially toxic superoxide14. Cellular swelling
occurs as a result of the ion influx. What is clear is that the affected area can be protected, at least in
animal models, by blockade of the NMDA receptor and recent clinical data suggest that such a
strategy may be effective in man11.
Recently, another metal ion has been implicated in neuronal damage after transient forebrain
ischaemia. It has been known for some time that Zn2+ is present in the terminals of central excitatory
neurones and is released along with glutamate during normal synaptic transmission The role of
Zn2+ is uncertain but it is known that it can act as an inhibitor of post-synaptic NMDA’and GABA-A
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receptors4 and voltage-dependent Ca2+ channels1 and therefore its release may be important in
limiting cell excitability. Zn2+ is also known to be toxic to neurones in culture, and this is mediated by
transport into the cell through NMDA receptors or Ca2+ channels3,5. Zn2+ is therefore both an
inhibitor of these channels and a substrate for them. In vivo, transient forebrain ischaemia in rat
leads to translocation of Zn2+ into those hippocampal neurones which are most vulnerable, before
degeneration sets in, suggesting that this is cause rather than effect15. Cell death can be
prevented by chelating extracellular Zn2+ with CaEDTA showing that intracellular Zn2+ is the culprit,
as suggested by the in vitro experiments6. This idea does not conflict with earlier ideas about
glutamate-induced Ca2+ entry as a causative event in cell death. Both could be required
simultaneously. Alternatively, the protective effect of NMDA receptor antagonists may be
explained by blockade of Zn2+ transport through the receptor ion channel6. This is reminiscent of
the demonstration that the in vitro neurotoxicity of Pb2+ can be blocked by NMDA receptor
antagonists16. The intracellular target for Zn2+ is not known. Zn2+ reacts with protein thiols and cell
death could result from generalized disruption of enzyme pathways without there necessarily being
any one single target.
Parkinson’s disease and Fe2+
Iron is another metal with a multitude of normal functions in biology, but which appears under certain
circumstances to contribute to neuronal cell death17. Free ferrous ions can reduce H202 to
produce hydroxyl radicals (Fenton reaction). At a slower rate, ferric chelates can also conver H202 to OH.. This most damaging of reactive oxygen species is normally prevented from forming by-the
action of catalase converting H202 to oxygen and water. The key to preventing iron toxicity is
therefore to ensure that iron is sequestered in such a way as to prevent it taking part in Fenton
chemistry. Iron in the body is complexed in haemoproteins, other metalloenzymes, and iron
transporting and storage proteins such as transferrin and ferritin. These chelates are poor Fenton
reagents, but some can be induced to release small quantities of iron following exposure to reactive
oxygen species such as 02. or H20218. The potential therefore exists for iron released locally in
response to oxidative stress to participate in Fenton chemistry leading in turn to further protein
damage.
The neurodegenerative disease in which iron has been most strongly implicated is Parkinson’s
disease19. This disease is characterised by selective and progressive loss of dopaminergic
neurones projecting from the substantia nigra to the striatum. The oxidative deamination of
dopamine by monoamine oxidase leads to the production of H202 which, as described above,
could lead to the production of toxic hydroxyl radicals. There have been many reports that the iron
content of parkinsonian substantia nigra pars compacta is elevated20. This in itself would not be
relevant if normal defensive mechanisms were in operation. However, while iron overload normally
induces expression of ferritin, in Parkinson’s disease brain, ferritin levels are reduced not
increased. Furthermore, other protective mechanisms seem to be deficient21 Catalase,
glutathione and ascorbate are reduced2 and increased levels of malondialdehyde2 have been
detected. This is a marker of lipid peroxidation, providing evidence that Parkinson’s brain tissue is
subject to attack by free radical species. The already unfavourable conditions may be further
exacerbated by the presence of melanin which arises in these dopaminergic neurones from
oxidation of dopamine. Melanin binds iron with high affinity and promotes iron-dependent lipid
peroxidation suggesting that the complex is a good Fenton reagent19. The involvement of iron in
Parkinson’s disease is not incompatible with ideas that the disease could be caused by an
endogenous neurotoxin. Conditions in these neurones appear to be such that they are vulnerable
to radical-mediated degeneration from whatever initial cause and that iron may play an important role
in the process.
Bipolar affective disorder, dorsoventral patterning and Li+
Lithium salts have been used now for many years for the effective treatment of bipolar affective
disorder or manic depression7. More recently, other drugs have been found to be effective
valproate and carbamazepine, for example23 but this has not shed any light on what is still a poorly
understood disease. The mechanism of lithium itself is still controversial. Since therapeutic plasma
levels of Li+ are about 0.5-1.4mM24 and the intracellular concentrations in neurones are unknown
but could be greater, one could pick from any number of processes which are affected by Li+ in the
mM range. Li+ mimics both Na+ and Mg2+ and therefore is potentially capable of modulating many
enzymes and transporters. Li+ is rather toxic at plasma levels two to three times the therapeutic
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level24, presumably as a result of inhibiting some other key process or processes. The question is
therefore whether there is a single target for the beneficial action of Li+ and how to identify it. Over
recent years, much attention has focused on the ability of Li+ to affect phosphoinositide signalling7.
The evidence is all circumstantial, but the hypothesis has attractive features in that it can explain the
selectivity of the drug through action on particular populations of overactive neurones25. The key
discovery was that the enzyme inositol monophosphatase was quite sensitive to inhibition by Li+
(Ki of around 0.1mM), and that the mode of inhibition, unusually, was uncompetitive26. The
enzyme is important in phosphoinositide signalling since it is responsible for regenerating inositol
for phosphoinositide synthesis (Fig.2). That is, receptor-mediated breakdown of
polyphosphoinositides to give inositol polyphosphate (IP3 and IP4) second messengers and
diacylglycerol would cease unless the inositol can be recycled25. Inositol monophosphatase is
involved both in the recycling and also in de novo synthesis from glucose, and the only other
source of inositol is therefore that which can be transported into the cell from outside sources
(dietary, for example). The attraction of the uncompetitive mode of inhibition of the enzyme by Li+
lay in the unusual property that uncompetitive inhibitors have less effect on enzyme activity and
metabolite levels when the enzyme is working at low capacity i.e. not saturated by its substrate, than
when it is working at higher capacity.
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This means that Li+ might be expected to have little effect on metabolite levels of the
phosphoinositide cycle when the cycle is not being stimulated by agonist action. However, in the
presence of an agonist, substrates (inositol monophosphates) would increase and inositol would
decrease. The former has been shown repeatedly in many in vitro cell systems27 and in vivo in rat28
and mouse29.
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Fig.3 Structure of L-690,330
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Our own work on the discovery of selective organic inhibitors of inositol monophosphatase
confirmed that the effects of Li+ on phosphoinositide cycle intermediates in vitro and in vivo could
be explained by underlying inhibition of this enzyme. Prodrugs of the inhibitor L-690,330 (Fig.3)
had very potent Li+-Iike effects on inositol phosphate levels (IP1, IP3 and IP4)in a cell line30, and L-
690,330 itself was capable of elevating IP1 in mouse brain3.
The question that has proven much harder to answer is whether inositol depletion occurs to any
extent. The consequences of inositol depletion would be a reduced rate of synthesis of
phosphoinositides resulting in reduced capacity for production of IP3 and IP4. This has been
shown in vitro in brain slices or cell lines in which the depletion of inositol also gives rise to a marked
increase in the other substrate for phosphoinositide synthesis, CMPPA32. By a reversal of the
normal reaction, this can lead to an increase in diacylglycerol. In vivo, the evidence that Li+, at
therapeutic levels, causes decreased cell signalling through this pathway is much harder to find.
Marked elevation of inositol monophosphates and a reciprocal decrease in brain inositol requires
high doses of Li+ and simultaneous treatment with an agonist, such as pilocarpine28. It can be
argued that since the effect is really only seen at high doses then this is more likely to be related to
the toxicity of Li+ than its therapeutic effect. The extent of the effect on the phosphoinositide cycle
depends not only on the extent to which Li+ is elevating inositol monophosphates but also on the
extent to which the cell can restore its inositol level through transport. This is controlled by a
balance between uptake and efflux pathways25. Since this balance can vary from cell to cell, some
cells are more vulnerable to inositol depletion than others and it may therefore be only a subset of
neurones which are affected by Li+. The remainder, despite inhibition of inositol
monophosphatase can limit the effect by maintaining intracellular inositol through transport while
others cannot, and signalling is decreased. The appeal of this theory is that it offers an explanation
for the in vivo selectivity of Li+, which by the standards of organic drugs, is a very unselective ligand.
To find further evidence for inositol depletion, various outcomes of Li+ in vivo have been examined
for their prevention by exogenous inositol. For example, the potentiating effect of Li+ on
pilocarpine-induced seizures is prevented by prior adminstration of myo-inositol i.c.v33. The belief
that selective action by myo-inositol (the isomer which is incorporated into phophoinositides) as
opposed to scyllo-inositol (which is not) provides adequate proof of the mechanism, was damaged
by the demonstration that epi-inositol could also prevent seizures34. Epi-inositol is not a substrate
for phosphoinositide synthesis. Very recently, another effect of Li+ which was prevented by myo-
inositol and thought therefore to be linked to the phosphoinositide cycle, was shown to be caused
by quite a different mechanism.
Lithium salts cause dorsalisation of Xenopus embryos, that is, duplication of anterior structures
such as the head, eyes and neural tube, at the expense of posterior structures such as the tail35. A
number of genes are implicated in dorsoventral patterning in vertebrates including a family of
glycoproteins36 which include Wnt-1 in mouse and Xwnt-8 in Xenopus. Work in Drosophila has
established that one of the genes involved in the wingless (equivalent to Wnt-1) signalling pathway
(shaggy or zw-3) is the homologue of a mammalian protein kinase, glycogen synthase kinase 337.
Injection of Xenopus embryos with dominant negative mutants of GSK-3 mimics the phenotype of
Li+ treatment i.e. loss of GSK,-3 leads to dorsalisation, while overexpression of the enzyme leads to
ventralisation38. The evidence that the effect of Li+ was via inhibition of inositol monophosphatase
was shown to be incorrect, since the specific inhibitor, L-690,330, did not cause dorsalisation
despite complete inhibition of the enzyme in the embryos39. In fact, Li+ is an uncompetitive
inhibitor of GSK-3, with a Ki in the mM range39. While not as potent an inhibitor of GSK-3 as inositol
monophosphatase, inhibition would occur at therapeutic plasma concentrations of Li+40. So, is
GSK-3 a plausible candidate for the action of Li+ in the treatment of psychiatric disorder? The
enzyme has a number of functions in addition to regulating glycogen synthesis. It is certainly
involved in insulin signalling and is itself regulated by a number of kinases via ser/thr
phosphorylation. Parenthetically, it is also known as tau protein kinase and has been suggested
to play a role in Alzheimer’s disease through mediating the cytotoxicity of the amyloid-( peptide41.
However, there is no answer to this question other than to test a selective inhibitor in the clinic.
Oxidative stress, neurodegeneration and organomanganese complexes
Reference has already been made to the possible role of reactive oxygen species in
neurodegeneration7. In stroke or other conditions leading to excessive glutamate release, the
influx of Ca2+ ions through the NMDA receptor can lead to activation of systems producing such
species (mitochondrial dysfunction, xanthine oxidase activation) and free radical scavenging may
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be a valid approach to therapy. There was great interest therefore in the aminosteroid "lazaroid",
tirilazad, from Upjohn, which showed excellent levels of neuroprotection in animal models of
traumatic brain damage42. Tirilazad is approved for the treatment of subarachnoid haemorrhage43,
but results in head injury and in stroke have not s open the question whether it is the concept or the
drug that is lacking.
Another approach which may help provide an answer is that of the organomanganese complexes
being developed by Eukarion. These compounds are able to catalyse dismutation of superoxide to
H202 and 02 as well as catalysing breakdown of H202 to 02 and water8. They therefore act as small
molecule superoxide dismutases and catalases. The relative activity of the two is determined by the
exact nature of the organic chelator. One of these compounds, EUK-8 (Fig.4), has been tested in a
number of model systems in which free radical species have been implicated as the toxic agents.
N
Fi. 4. Structure of
In the neuroscience area, EUK-8 has been shown to prevent the deterioration of synaptic activity in
rat hippocampal slices subjected to hypoxia and acidosis, a possible indicator of activity in the
treatment of stroke45. In vivo central activity of EUK-8 has also been shown in mice following
treatment with the neurotoxins, MPTP and 6-hydroxydopamine46. These agents cause selective
loss of dopaminergic neurones and MPTP in particular is used to generate a primate model of
Parkinson’s disease. The similarity between drug-induced and idiopathic parkinsonism has done
much to fuel speculation that an environmental neurotoxin may be a key factor in the disease.
However, these two toxins are known to cause cell death throuqh a free-radical mediated process
and systemic or intracerebrovascular EUK-8 provided p’otection against MPTP and 6-
hydroxydopamine respectively46.
More controversial by far is the idea that the amyloid-( peptide is the direct cause of neuronal death
in Alzheimer’s disease and that it does so through a free-radical process. Familial Alzheimer’s
disease results from mutations in either the amyloid precursor protein, APP, or in either of the two
presenilins ,1 and 2,(PS1 a.nd. PS2)_47. Despite any good understanding of the normal role of APP or
the preseniins, or now mutation of the latter proteins affects the processing of the former, it is now
clear that all the mutations lead to altered APP processing such that there is either an increased
production of A( peptides in general or a selective increase in the longer 42-43 aminoacid form.
The latter is more prone to aggregate into a state which is toxic to cells in vitro and this therefore
provides an explanation for early onset Alzheimer’s disease. The cause of sporadic Alzheimer’s
disease of course, is not explained by this mechanism even though A( may be the toxic agent.
Moreover, despite a huge effort from many laboratories, there is no concensus on how A( kills cells.
Certainly, reactive oxygen species have been proposed as the culprits and antioxidants have some
efficacy in preventing acute cell death caused by A( in vitro48. EUK-8 is one of these and provides
protection against A(-induced cell death in organotypic hippocampal cultures, preventing cell lysis
and reducing levels of reactive oxygen species49. It is difficult to know how good a model of
Alzheimer’s disease this is, and in the absence of an animal model with Alzheimer-like neuronal
degeneration, the efficacy of this and similar drugs will have to be tested in the clinic.
Conclusions
The use of the simple cation, Li+, as a therapeutic agent is unique and it is hard to see what lessons
can be learned from it, particularly as its site of action is still not understood. Since the most
plausible mechanisms at present involve action on intracellular signalling pathways, Li+ may be a
pointer to the potential of drugs acting on these pathways as an alternative to the current reliance
on cell surface receptor agonists and antagonists. This being said, the justification for metal binding
sites as a good means of modulating protein function is not clear, certainly while we do not
understand exactly how Li+ acts. By modern standards, Li+ would not be an acceptable drug,
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having a very poor therapeutic index. Careful use has allowed it to become a successful drug, but
the toxicity is a real problem which may be mechanism-based but may also be a reflection of lack of
specificity of Li+ for the metal binding site of its target protein. In the same way, the toxicity of
divalent and trivalent metal ions is likely to be exerted on a wide range of different targets and
intervention strategies should reflect this. Metal-chelation approaches therefore have merit in that
they avoid the need to identify the molecular targets of the toxic metal ion, and would also be
effective in circumstances where the toxicity is indirect, for example, where production of free
radical species is the basis of the disorder. Metal chelators have been shown to have effects in
animal models in preventing neurodegeneration. In an example given above, CaEDTA prevented
cell death in a stroke model. The iron chelator, desferrioxamine i.c.v, prevents loss of dopaminergic
neurones following administration of 6-hydroxydopamine to rat50. The same compound is effective
orally in reducing aluminium in brain and peripheral tissues of aluminium-loaded rats5 and
desferrioxamine is used to treat aluminium-related osteomalacia and dialysis dementia in renal
dialysis patients. However, evidence for efficacy of chelation strategies in major neurodegenerative
disease is much less convincing. The epidemiological evidence for aluminium as a risk factor for
Alzheimer’s disease as well as the evidence for aluminium as a causative factor in dialysis dementia
prompted a clinical trial of desferrioxamine in this disease, the results of which were unconvincing52.
An alternative way to chelate metals more effectively would be to increase expression of natural
chelators. Reference has already been made above to the reduction in ferritin in Parkinson’s
disease brain. Interest has also centred around the metallothioneins, in particular, MT-III, which is
expressed in the glutamatergic pyramidal cells of the hippocampus and granule cells of the dentate
gyrus among others53. It has been proposed that MT-III is involved in zinc homeostasis and
indirectly therefore in modulating glutamatergic transmission. A role for MT-III in Alzheimer’s diease
and other neurodegenerative disorders remains controversial, but the idea that manipulating
expression of MT’s might be an approach to neuroprotection is intriguing.
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